Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

Abstract Introduction The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with migraine who are treated with mAbs....

Full description

Bibliographic Details
Published in:Neurology and Therapy
Main Authors: Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Subjects:
CGRP mAbs
Erenumab
Eptinezumab
Gepants
Migraine
Safety
Online Access:https://doi.org/10.1007/s40120-024-00586-w

Internet

https://doi.org/10.1007/s40120-024-00586-w

Similar Items